NovaDigm Therapeutics Inc is a biotechnology company based in Grand Forks, ND, dedicated to developing innovative immunotherapeutics and preventative vaccines for fungal and bacterial diseases. Their lead development candidate, NDV-3A, has shown promising preclinical efficacy in reducing the severity of diseases caused by both fungal and bacterial pathogens, making it a potential breakthrough in the field.
Currently in Phase 2 clinical development for recurrent vulvovaginal candidiasis (RVVC), NDV-3A is also being explored for future indications in Candida, including nosocomial candidiasis, a severe and life-threatening infection, as well as Staphylococcus aureus, including MRSA. NovaDigm Therapeutics aims to address the challenges of recurrent, drug-resistant, and potentially life-threatening fungal and bacterial diseases through their innovative approach.
Generated from the website